Search

Paul F Stabila

from Coventry, RI
Age ~59
Get Report
Also known as:
Paul R Stabila, Paul Stabili
Phone and address:
1 Spring Valley Ln, Coventry, RI 02816
(401) 527-7613
Related to:
Salvador P Stabila, 63
Connected to:
Brandon J Stabile, 36Carmen Stabile, 62Devin T Stabile, 28Diane Stabile, 60Jeremy Z Stabile, 47Jill Stabile, 62Joseph Stabile, 35Kerri Stabile, 60Krista M Stabile, 37Livia C Stabile, 45

Paul Stabila Phones & Addresses

  • 1 Spring Valley Ln, Coventry, RI 02816 (401) 527-7613
  • 9 Hickory Rd, Coventry, RI 02816
  • Colchester, VT
  • Norfolk, MA
  • La Jolla, CA
  • 1 Spring Valley Ln, Coventry, RI 02816

Work

Position: Clerical/White Collar

Education

Degree: Associate degree or higher

Publications

Us Patents

Arpe-19 As A Platform Cell Line For Encapsulated Cell-Based Delivery

View page
US Patent:
7115257, Oct 3, 2006
Filed:
Apr 6, 2000
Appl. No.:
09/958040
Inventors:
Weng Tao - Lincoln RI, US
David H. Rein - Cambridge MA, US
Brenda J. Dean - Cumberland RI, US
Paul F. Stabila - Coventry RI, US
Moses B. I. Goddard - Tiverton RI, US
Assignee:
Neurotech S.A. - Evry
International Classification:
A61K 48/00
C12N 15/12
C12N 15/00
C12N 15/09
US Classification:
424 9321, 424 932, 4353201
Abstract:
ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.

Micronized Device For The Delivery Of Biologically Active Molecules And Methods Of Use Thereof

View page
US Patent:
7820195, Oct 26, 2010
Filed:
Dec 18, 2006
Appl. No.:
11/641479
Inventors:
Konrad Kauper - Sutton MA, US
Paul Stabila - Coventry RI, US
Weng Tao - Lincoln RI, US
Assignee:
Neurotech USA, Inc. - Lincoln RI
International Classification:
A61K 9/50
A61K 9/51
US Classification:
424427, 424400
Abstract:
The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from.

Arpe-19 As Platform Cell Line For Encapsulated Cell-Based Delivery

View page
US Patent:
20070071734, Mar 29, 2007
Filed:
Oct 3, 2006
Appl. No.:
11/543015
Inventors:
Weng Tao - Lincoln RI, US
David Rein - Cambridge MA, US
Brenda Dean - Cumberland RI, US
Paul Stabila - Coventry RI, US
Moses Goddard - Tiverton RI, US
International Classification:
A61K 48/00
A61F 2/02
US Classification:
424093210, 424423000, 424427000
Abstract:
ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.

Arpe-19 As A Platform Cell Line For Encapsulated Cell-Based Delivery

View page
US Patent:
20090269319, Oct 29, 2009
Filed:
Jul 8, 2009
Appl. No.:
12/499403
Inventors:
Weng Tao - Lincoln RI, US
David H. Rein - Cambridge MA, US
Brenda J. Dean - Cumberland RI, US
Paul F. Stabila - Coventry RI, US
Moses B.I. Goddard - Tiverton RI, US
Assignee:
NEUROTECH USA, INC. - Lincoln RI
International Classification:
A61K 45/00
A61P 35/00
US Classification:
424 937
Abstract:
ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.

Arpe-19 As A Platform Cell Line For Encapsulated Cell-Based Delivery

View page
US Patent:
20090269389, Oct 29, 2009
Filed:
Jul 7, 2009
Appl. No.:
12/498737
Inventors:
Weng Tao - Lincoln RI, US
David H. Rein - Cambridge MA, US
Brenda J. Dean - Cumberland RI, US
Paul F. Stabila - Coventry RI, US
Moses B.I. Goddard - Tiverton RI, US
Assignee:
NEUROTECH USA, INC. - Lincoln RI
International Classification:
A61P 9/00
C12N 5/08
A61P 43/00
US Classification:
424425, 435366, 424424
Abstract:
ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.

Cell Lines That Produce Prostaglandin F2 Alpha (Pgf2A) And Uses Thereof

View page
US Patent:
20100272780, Oct 28, 2010
Filed:
Apr 21, 2010
Appl. No.:
12/764575
Inventors:
Vincent Ling - Walpole MA, US
Weng Tao - Lincoln RI, US
Konrad Kauper - Sutton MA, US
Paul Stabila - Coventry RI, US
International Classification:
A61F 2/00
C12N 15/63
C12N 5/10
A61P 27/02
A61K 31/5575
US Classification:
424427, 4353201, 435371, 514573
Abstract:
The invention provides cells and cell lines the are genetically modified to express the hCox-2 enzyme, which, in turn, results in the upregulation of prostaglandin F2 alpha (PGF2a) production. The invention also provides encapsulated cell therapy devices containing such cells or cell lines that are capable of delivering PGF2a as well as methods of using these devices to deliver PGF2a to the eye and to treat ophthalmic disorders in patients suffering therefrom.

Use Of Pedf In An Encapsulated Cell-Based Delivery System

View page
US Patent:
20110111008, May 12, 2011
Filed:
Oct 6, 2010
Appl. No.:
12/899026
Inventors:
Weng Tao - Lincoln RI, US
Konrad Kauper - Sutton MA, US
Paul Stabila - Coventry RI, US
Vincent Ling - Walpole MA, US
International Classification:
A61F 2/00
A61K 35/12
C12N 11/02
A61F 9/007
US Classification:
424428, 424 937, 435177, 604175
Abstract:
The invention relates to a device for delivery of pigment epithelium derived factor (PEDF) to the eye utilizing encapsulated PEDF-secreting cells and related methods for the treatment and prevention of ophthalmic diseases and disorders.

Micronized Device For The Delivery Of Biologically Active Molecules And Methods Of Use Thereof

View page
US Patent:
20110236457, Sep 29, 2011
Filed:
Dec 18, 2006
Appl. No.:
12/087089
Inventors:
Konrad Kauper - Sutton MA, US
Weng Tao - Lincoln RI, US
Paul Stabila - Coventry RI, US
International Classification:
A61K 9/48
A61K 9/00
A61P 27/02
A61P 27/06
A61P 27/12
US Classification:
424424, 424427, 424 931
Abstract:
The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from.
Control profile
Paul F Stabila from Coventry, RI, age ~59 Get Report